Shares of Atyr Pharma Inc. (NASDAQ:LIFE) traded down 5.5% during trading on Thursday . The company traded as low as $2.88 and last traded at $2.93, with a volume of 267,473 shares. The stock had previously closed at $3.10.

A number of analysts recently commented on the company. BMO Capital Markets assumed coverage on Atyr Pharma in a research note on Monday, April 11th. They issued a “market perform” rating for the company. Zacks Investment Research raised Atyr Pharma from a “sell” rating to a “buy” rating and set a $3.50 price target for the company in a research note on Tuesday, May 31st. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $23.75.

The stock’s market capitalization is $80.77 million. The company’s 50-day moving average is $2.85 and its 200 day moving average is $3.96.

Atyr Pharma (NASDAQ:LIFE) last issued its quarterly earnings data on Wednesday, May 11th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.70) by $0.02. On average, equities research analysts forecast that Atyr Pharma Inc. will post ($2.79) EPS for the current fiscal year.

In other news, insider Grove Matsuoka acquired 12,412 shares of the firm’s stock in a transaction dated Wednesday, May 11th. The shares were acquired at an average cost of $3.04 per share, with a total value of $37,732.48. Following the acquisition, the insider now directly owns 2,412 shares of the company’s stock, valued at $7,332.48. The transaction was disclosed in a document filed with the SEC, which is available at this link.

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.